Skip to content

EV / sales at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
2.7×-1.4×
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
5.1×-0.9×
Danaher logo
DanaherDHR
-0.8×
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
1.5×-0.1×
10x Genomics, Inc. logo
10x Genomics, Inc.TXG
3.6×+2.4×
TEC
Bio-TechneTECH
6.8×-1.1×

Other financials

Income statement

See full
Revenue$44.1M+6.5%
Gross profit$21.3M+5.4%
Operating income-$18.5M-23.3%
Net income-$18.9M-65.5%
EPS (diluted)-$0.15-66.7%

Balance sheet

See full
Cash & equivalents$31.8M-66.6%
Total debt$16.8M+40.9%
Total equity$327.6M-13.7%
Total assets$449.1M-6.9%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+155%
Free cash flow-$4.9M-403%

Valuation

See full
Market cap$577.27M+54.5%
Enterprise value$562.23M+93.7%
P/S2.8×+0.9×

Profitability

See full
Gross margin51.7%-3.2pp
Operating margin-21.5%
Net margin-36.2%
FCF margin-6.2%-15.1pp

Returns & leverage

See full
Return on equity-20.9%
Debt / equity0.1×0.0×
Current ratio4.7×-0.9×

Where this comes from

Calculated from Cytek Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytek Biosciences, Inc.'s ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytek Biosciences, Inc.'s EV / sales?
Cytek Biosciences, Inc. (CTKB) reported EV / sales of 2.7× in Q1 2026.
How has Cytek Biosciences, Inc.'s EV / sales changed year-over-year?
Cytek Biosciences, Inc.'s EV / sales increased by 22.6% year-over-year, from 2.2× to 2.7×.
What is the long-term trend for Cytek Biosciences, Inc.'s EV / sales?
Over 4 years (2021 to 2025), Cytek Biosciences, Inc.'s EV / sales has grown at a -31.6% compound annual growth rate (CAGR), from 14.3× to 3.1×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.